The Latest Breaking News from Antares

That hard-tuned, robot-like sound, first popularised by Cher, has now become something of a staple in modern pop

Released this week, the latest version of Auto-Tune Pro can layer up to four notes of tuned vocal simultaneously in response to MIDI input

Antares Pharma Inc (NASDAQ: ATRS) shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc (NASDAQ: HALO) for $5.60 per share in cash, valuing Antares at

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal

Halozyme Therapeutics Inc (NASDAQ:HALO) will acquire Antares Pharma Inc (NASDAQ:ATRS) for $5.60 per share, valuing Antares at approximately $960 million. The transaction is expected to be accretive to Halozyme's 2022 revenue and adjusted earnings and accelerate top-and bottom-line growth through 2027, with multiple growth drivers beyond 2027.  Antares' suite of FDA-approved and partner products utilizing…

Antares Pharma Inc (NASDAQ:ATRS) has nabbed another FDA approval, and the Company's second involving testosterone. The Company announced FDA approval for Tlando (testosterone undecanoate), an oral treatment for testosterone replacement therapy indicated for deficiency or absence of endogenous testosterone or hypogonadism. The first time the Company got a testosterone product approved by…

Here's a roundup of top developments in the biotech space over the last 24 hours:

By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT